With the new strategy, published in the journal Neurology, the percentage of diag-nosed cases has doubled, new diseases and their genetic cause have been dis-covered, and the described clinical pictures have been extended.
A new genomic medicine strategy improves the diagnostic of leukodystrophies Read More »
The Human Resources Strategy for Researchers (HRS4R) supports institutions and research centers in the implementation of human resources initiatives that promote the researchers’ attraction and the development of the research career.
On December 26, Dr. Miquel Rutllant left us. He was a key person in the creation of what we now know as IDIBELL and one of the forerunners of biomedical research in our country.
The forerunner of IDIBELL Dr. Miquel Rutllant has died Read More »
It is proven that SARS-CoV-2 infection manifests in very different ways: some cases simply show mild discomfort for a few days, others need to be admitted to the ICU and some others even go through it without experiencing any kind of symptom. There are also cases where a person, despite having been living with a
What are the genetic reasons behind resistance to COVID-19? Read More »
STARS GAME is a 3-year project that revolves around the co-creation of a digital escape room, in which both the students collective (between 10 and 13 years old) participate, through classroom workshops, together with faculty and scientific research and also communication professionals from the four countries
Sinergia Innova is an initiative of the L’Hospitalet City Council to promote open innovation in the biomedical sector.
When the year ends it is a good time to look back and review the challenges achieved in the last twelve months. More than 1,300 scientific articles, of which 550 are led by IDIBELL, show that there many objectives have been achieved, but there are also many questions that remain to be answered.
We close a 2021 full of science! Read More »
A research group from IDIBELL has identified genes relevant to the oxidative stress response that could help design new treatments for cystic fibrosis.
Finding new paths in the treatment of cystic fibrosis Read More »
Two studies published in The New England Journal of Medicine, with the participation of IDIBELL and the ICO, present the results of two phase 3 clinical trials comparing treatment with CART lymphocytes versus conventional treatment with chemotherapy and bone marrow transplantation.
A team from IDIBELL, the Bellvitge University Hospital and CIBERSAM, in collaboration with ISGlobal and Harvard Medical School, have described alterations in two genes that would explain the abnormally reverberant behavior of the brain circuits involved in OCD.
